

# Realief® Neuropathy Therapy Patient Outcomes Data

## Patient Profiles<sup>1</sup>

Number of patients: 1339  
 Age: Range - 14 to 99; Average - 70  
 Gender: 62% Male; 38% Female  
 Years since symptom onset: Range - 0.1 to 58; Average - 7  
 Number of initial Realief treatments: Range - 6 to 19; Average - 14

Cause of Neuropathy	
Idiopathic/unknown	59%
Diabetic	19%
Chemotherapy	7%
All other	15%

Symptom Presentation	
Legs only	68%
Hands only	1%
Both legs and hands	31%
Pain	44%
Tingling	69%
Numbness	89%
Hot/cold sensations	43%
Tightness	81%

## INITIAL PHASE THERAPY OUTCOMES<sup>2</sup>

PAIN INTENSITY			
FEET/LEGS		HANDS/ARMS	
Patients experiencing symptom relief	94%	Patients experiencing symptom relief	96%
Patients experiencing 100% relief	65%	Patients experiencing 100% relief	61%
Average reduction of symptom	79%	Average reduction of symptom	78%

PAIN SURFACE AREA AFFECTED			
FEET/LEGS		HANDS/ARMS	
Patients experiencing symptom relief	91%	Patients experiencing symptom relief	88%
Patients experiencing 100% relief	65%	Patients experiencing 100% relief	61%
Average reduction of symptom	82%	Average reduction of symptom	78%

TINGLING SURFACE AREA AFFECTED			
FEET/LEGS		HANDS/ARMS	
Patients experiencing symptom relief	92%	Patients experiencing symptom relief	85%
Patients experiencing 100% relief	58%	Patients experiencing 100% relief	59%
Average reduction of symptom	80%	Average reduction of symptom	74%

<sup>1</sup> This data is part of an active registry and includes all consented patients who completed 6 or more treatments as of 11/1/11, from 6 active centers.

<sup>2</sup> Outcomes data from left leg and left arm are shown, as these accounted for the most severe initial symptoms. Difference in outcomes data from right leg and right arm are not statistically significant. Measurements reflect the change from max measured symptom to last measured during initial treatment phase of care.

# Realief® Neuropathy Therapy Patient Outcomes Data

## INITIAL PHASE THERAPY OUTCOMES

### NUMBNESS SURFACE AREA AFFECTED

FEET/LEGS		HANDS/ARMS	
Patients experiencing symptom relief	97%	Patients experiencing symptom relief	91%
Patients experiencing 100% relief	30%	Patients experiencing 100% relief	68%
Average reduction of symptom	79%	Average reduction of symptom	82%

### HOT/COLD SURFACE AREA AFFECTED

FEET/LEGS		HANDS/ARMS	
Patients experiencing symptom relief	92%	Patients experiencing symptom relief	85%
Patients experiencing 100% relief	66%	Patients experiencing 100% relief	70%
Average reduction of symptom	82%	Average reduction of symptom	80%

### TIGHTNESS SURFACE AREA AFFECTED

FEET/LEGS		HANDS/ARMS	
Patients experiencing symptom relief	77%	Patients experiencing symptom relief	68%
Patients experiencing 100% relief	19%	Patients experiencing 100% relief	40%
Average reduction of symptom	52%	Average reduction of symptom	54%

### RESULTS BY VARIOUS CAUSES OF NEUROPATHY

Cause	% of Total	Average Symptom Relief	% Reduction mTNS*	Starting RNSS**	Ending RNSS**
Idiopathic/unknown	59%	82%	-51%	30.7	8.3
Diabetic (DPN)	19%	81%	-47%	30.9	8
Chemo induced (CIPN)	7%	83%	-54%	31.7	7.4
All other causes	15%	76%	-55%	33	8.8

\* mTNS is a validated tool that assess six domains of peripheral neuropathy including motor, reflex and balance

\*\* RNSS is a composite measure of all recorded signs and symptoms

### STRENGTH AND BALANCE<sup>3</sup>

Patients with initial balance impairment who experience improvement in <b>BALANCE</b>	73%
Patients with motor symptoms (issues walking, climbing stairs, combing hair,...) impairment who experienced improvement in <b>MOTOR SYMPTOMS</b>	83%

<sup>3</sup> Measurements compared were from the first initial care treatment compared to the last initial care treatment